Exactech, Inc. (EXAC) Receives Average Rating of “Hold” from Analysts

Shares of Exactech, Inc. (NASDAQ:EXAC) have earned an average recommendation of “Hold” from the seven analysts that are covering the firm, MarketBeat reports. Six analysts have rated the stock with a hold rating. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $49.00.

Several equities analysts have recently commented on the company. Zacks Investment Research raised Exactech from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. Robert W. Baird reaffirmed a “hold” rating and issued a $49.00 target price on shares of Exactech in a research report on Thursday, December 7th. ValuEngine downgraded Exactech from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Gabelli downgraded Exactech from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, Sidoti downgraded Exactech from a “buy” rating to a “neutral” rating in a research report on Monday, October 23rd.

Exactech (NASDAQ EXAC) traded up $1.15 during trading on Monday, hitting $50.50. The stock had a trading volume of 326,889 shares, compared to its average volume of 130,660. Exactech has a 52 week low of $23.30 and a 52 week high of $50.95. The company has a quick ratio of 2.09, a current ratio of 4.08 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $711.30, a P/E ratio of 2,525.00, a price-to-earnings-growth ratio of 3.65 and a beta of 1.02.

Exactech (NASDAQ:EXAC) last posted its earnings results on Monday, October 30th. The medical equipment provider reported $0.20 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.03). Exactech had a net margin of 0.18% and a return on equity of 7.22%. The firm had revenue of $61.40 million during the quarter, compared to analyst estimates of $61.78 million. sell-side analysts predict that Exactech will post 1.29 EPS for the current year.

Several hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company boosted its stake in shares of Exactech by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 9,323 shares of the medical equipment provider’s stock valued at $278,000 after buying an additional 289 shares during the period. Teachers Advisors LLC boosted its stake in shares of Exactech by 2.7% in the second quarter. Teachers Advisors LLC now owns 21,549 shares of the medical equipment provider’s stock valued at $642,000 after buying an additional 568 shares during the period. California Public Employees Retirement System boosted its stake in shares of Exactech by 4.5% in the second quarter. California Public Employees Retirement System now owns 23,100 shares of the medical equipment provider’s stock valued at $688,000 after buying an additional 1,000 shares during the period. Numeric Investors LLC boosted its stake in shares of Exactech by 4.4% in the second quarter. Numeric Investors LLC now owns 30,643 shares of the medical equipment provider’s stock valued at $913,000 after buying an additional 1,300 shares during the period. Finally, Alliancebernstein L.P. boosted its stake in shares of Exactech by 6.1% in the second quarter. Alliancebernstein L.P. now owns 24,456 shares of the medical equipment provider’s stock valued at $729,000 after buying an additional 1,400 shares during the period. Institutional investors and hedge funds own 66.30% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.com-unik.info/2018/01/08/exactech-inc-exac-receives-average-rating-of-hold-from-analysts.html.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

What are top analysts saying about Exactech? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exactech and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit